Compare Indoco Remedies with India Infoline - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs IIFL FINANCE - Comparison Results

INDOCO REMEDIES     Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

IIFL FINANCE 
   Change

India Infoline is one of the oldest and leading players in the Indian broking services space. Besides offering the entire gamut of financial services covering investment products ranging from equities and derivatives, commodities and portfolio manage... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES IIFL FINANCE INDOCO REMEDIES/
IIFL FINANCE
 
P/E (TTM) x 52.0 4.6 1,135.9% View Chart
P/BV x 2.0 0.9 221.9% View Chart
Dividend Yield % 0.7 3.4 19.5%  

Financials

 INDOCO REMEDIES   IIFL FINANCE
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-18
IIFL FINANCE
Mar-18
INDOCO REMEDIES/
IIFL FINANCE
5-Yr Chart
Click to enlarge
High Rs317873 36.4%   
Low Rs178395 45.1%   
Sales per share (Unadj.) Rs113.1119.5 94.6%  
Earnings per share (Unadj.) Rs4.519.6 22.8%  
Cash flow per share (Unadj.) Rs11.820.1 58.8%  
Dividends per share (Unadj.) Rs1.005.00 20.0%  
Dividend yield (eoy) %0.40.8 51.2%  
Book value per share (Unadj.) Rs73.2158.8 46.1%  
Shares outstanding (eoy) m92.15318.98 28.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.25.3 41.3%   
Avg P/E ratio x55.532.4 171.1%  
P/CF ratio (eoy) x21.031.5 66.5%  
Price / Book Value ratio x3.44.0 84.7%  
Dividend payout %22.425.6 87.6%   
Avg Mkt Cap Rs m22,830202,233 11.3%   
No. of employees `0005.50.1 10,490.4%   
Total wages/salary Rs m2,2094,615 47.9%   
Avg. sales/employee Rs Th1,910.1733,196.0 0.3%   
Avg. wages/employee Rs Th405.088,746.2 0.5%   
Avg. net profit/employee Rs Th75.5119,996.2 0.1%   
INCOME DATA
Net Sales Rs m10,41938,126 27.3%  
Other income Rs m47415 11.3%   
Total revenues Rs m10,46638,542 27.2%   
Gross profit Rs m1,34927,815 4.9%  
Depreciation Rs m677173 391.2%   
Interest Rs m23518,968 1.2%   
Profit before tax Rs m4849,089 5.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m722,850 2.5%   
Profit after tax Rs m4126,240 6.6%  
Gross profit margin %12.973.0 17.8%  
Effective tax rate %15.031.4 47.7%   
Net profit margin %4.016.4 24.1%  
BALANCE SHEET DATA
Current assets Rs m5,373215,405 2.5%   
Current liabilities Rs m4,157240,168 1.7%   
Net working cap to sales %11.7-65.0 -18.0%  
Current ratio x1.30.9 144.1%  
Inventory Days Days682 3,441.7%  
Debtors Days Days7325 292.6%  
Net fixed assets Rs m6,2447,251 86.1%   
Share capital Rs m184638 28.9%   
"Free" reserves Rs m6,56650,019 13.1%   
Net worth Rs m6,75050,657 13.3%   
Long term debt Rs m1,233127,110 1.0%   
Total assets Rs m12,363437,033 2.8%  
Interest coverage x3.11.5 206.8%   
Debt to equity ratio x0.22.5 7.3%  
Sales to assets ratio x0.80.1 966.1%   
Return on assets %5.25.8 90.7%  
Return on equity %6.112.3 49.5%  
Return on capital %9.015.8 57.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3,7620-   
Fx outflow Rs m1,1430-   
Net fx Rs m2,6190-   
CASH FLOW
From Operations Rs m1,227-69,552 -1.8%  
From Investments Rs m-1,360-1,805 75.3%  
From Financial Activity Rs m-38866,452 -0.6%  
Net Cashflow Rs m-521-6,948 7.5%  

Share Holding

Indian Promoters % 59.2 30.7 192.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 0.8 1,562.5%  
FIIs % 6.0 44.4 13.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 24.2 92.6%  
Shareholders   12,805 27,982 45.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   CCL INTERNATIONAL  THOMAS COOK INDIA  TALWALKARS BETTER VALUE  MOTILAL OSWAL  ADANI PORTS & SEZ  



Today's Market

Why is Sensex at a Record High When Economy is in Trouble?(Podcast)

In today's episode, I talk about all the major moves of the week, including Modi government's blockbuster disinvestment, developments in the telecom sector.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (2QFY20); Net Profit Up 194.1% (Quarterly Result Update)

Nov 5, 2019 | Updated on Nov 5, 2019

For the quarter ended September 2019, INDOCO REMEDIES has posted a net profit of Rs 73 m (up 194.1% YoY). Sales on the other hand came in at Rs 3 bn (up 23.9% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Jun 6, 2019 | Updated on Jun 6, 2019

For the quarter ended March 2019, INDOCO REMEDIES has posted a net profit of Rs 116 m (down 43.3% YoY). Sales on the other hand came in at Rs 3 bn (down 6.5% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

IIFL HOLDINGS Announces Quarterly Results (4QFY19); Net Profit Up 208.5% (Quarterly Result Update)

May 16, 2019 | Updated on May 16, 2019

For the quarter ended March 2019, IIFL HOLDINGS has posted a net profit of Rs 3 bn (up 208.5% YoY). Sales on the other hand came in at Rs 14 bn (up 38.6% YoY). Read on for a complete analysis of IIFL HOLDINGS's quarterly results.

INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

I Think Nestle, HUL, and Asian Paints Could Give Low Returns(Profit Hunter)

Nov 15, 2019

If you think high quality stocks will continue their dream run forever, then you must read this now.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Nov 22, 2019 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 8-QTR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS